Compare Chevron Corp (CVX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Zimmer Biomet Holdings Inc — how do they compare? Chevron Corp trades at $211.98 (market cap $414.98B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Chevron Corp is far larger — about 24.5× Zimmer Biomet Holdings Inc's market cap, and Chevron Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CVX | ZBH | |
|---|---|---|
Market Cap | $414.98B | $16.95B |
Volume | 7,575,112 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $217.73 | $103.98 |
52-Week Low | $146.72 | $79.58 |
Typical Hold Time | 101 Days | 89 Days |
Enterprise Value | $443.52B | $24.02B |
Dividend Yield | 3.37% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 3.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust cash flow from operations of $33.94B in 2025 and a dividend of $1.78 per share. However, revenue and net income have declined from 2022 peaks, with 2025 revenue at $184.43B and net income at $12.30B. Analyst consensus is bullish with a $208.31 price target, though geopolitical tensions and oil price volatility pose risks.
The outlook for CVX is cautiously optimistic, driven by high oil prices and strategic investments like the $13.8B Argentina project. Investment opportunities include a solid dividend yield and potential upside from production growth. Key risks are exposure to fluctuating oil prices, geopolitical instability affecting supply chains, and declining profit margins. Investors should weigh strong cash generation against cyclical industry pressures.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
